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Feijoada is one of the most typical dishes of
Brazilian cuisine, commonly made from a
mixture of black beans and several cuts of
pork and beef. It is served with rice, farofa
(toasted, seasoned manioc flour), sautéed
collard greens, and sliced oranges, among
other side orders. In themost sophisticated
recipes it can take more than 30 ingredi-
ents, including spices and side dishes. One
does not have to be a cook, chef, or expert
to distinguish beans—the main ingredient
of the dish—from complete feijoada.
Marijuana, the popular name of
Cannabis sativa, has more than 400
compounds, many of which are named
“cannabinoids” (substances that affect
receptors carrying the same name) (Pate,
2002). In an analogy with feijoada,
9-tetrahydrocannabinol (9-THC),
responsible for the psychoactive effects
of the drug (Zuardi, 2008), could be the
beans.
In the early twentieth century, when
the active principles of the drug had
not yet been isolated, marijuana extracts
were marketed by large pharmaceuti-
cal companies for a number of indica-
tions (Fankhauser, 2002). However, the
therapeutic use declined within a few
years due to the difficulty in obtaining
reproducible effects and to the introduc-
tion of other drugs for the same indi-
cations of marijuana at that moment.
Marijuana extracts have a wide variabil-
ity in their composition, stability, and
potency. Thus, consonant with the princi-
ples of the evolution of pharmacotherapy,
effort has been put into the development
of purer cannabinoid compounds that
can be accurately measured, thus reduc-
ing the risk of significant undesirable side
effects.
In the first half of the 1960s the
chemical structures of the major cannabi-
noids were determined by Professor
Raphael Mechoulam from Israel, includ-
ing 9-THC. Around 80 cannabinoids
have been described to date, with different
effects and many with therapeutic
potential.
Cannabidiol (CBD), for example,
which makes up to 40% of marijuana
extracts, has several effects opposite to
those of 9-THC, including anxiolytic
and antipsychotic properties (Crippa et al.,
2010). Differently from 9-THC, the use
of CBD alone does not cause the typi-
cal effects of marijuana, and Brazilian,
American, British, and Israeli groups
are in the leading edge of research on
the therapeutic potential of this com-
pound (Carlini, 2010). Today, CBD is
being tested in Brazil in Parkinson’s
disease, schizophrenia, social phobia,
post-traumatic stress disorder, smoking,
epilepsy, depression, and other conditions
(Crippa et al., 2010; Schier et al., 2012).
It can be said, therefore, that cannabi-
noids are components of marijuana, but
that the two are not synonyms. That is,
cannabinoids are not marijuana.
Marijuana is the most commonly used
illicit drug in many countries, despite evi-
dence showing that it may cause transient
psychiatric symptoms and cognitive alter-
ations depending on the dose. Moreover,
chronic marijuana use may also cause
long-lasting cognitive alterations and trig-
ger the onset of psychiatric disorders
in vulnerable individuals, depending on
the dose, frequency, and earliness of use
(Solowij et al., 2002; Manrique-Garcia
et al., 2012), although these findings are
still under debate.
The marijuana withdrawal syn-
drome has gained increased recognition
and it is known that some individuals
may develop dependence (Hasin et al.,
2008). Currently available therapeutic
interventions—both pharmacological and
non-pharmacological—have shown less
than optimal efficacy. Modern neuroimag-
ing studies show alterations in brain
function with chronic, repeated use of
marijuana (Bhattacharyya et al., 2012).
Furthermore, clinical complications such
as cancer and breathing and immunolog-
ical problems have also been associated
with the use of the drug. However, as
cannabis is often smoked in conjunction
with tobacco and/or other drugs, the rela-
tionship between chronic use and these
problems is so far inconclusive (Lader,
2009).
Therefore, the effects of chronic mar-
ijuana use on health need careful evalu-
ation. The existing evidence about these
effects is also confounded and misleading,
as it considers marijuana and cannabi-
noids to be equivalent.
All scientific debate concerning the
legalization of marijuana should necessar-
ily be informed by empirical data from
clinical trials and epidemiological studies.
Any debate occurring on a background
of political positions, ideological biases
and, even worse, personal beliefs will only
increase confusion, and postpone concrete
decisions.
Cannabinoids and drugs that act in the
endocannabinoid system have been shown
to have a fantastic therapeutic potential
and there is reason to believe that they
could benefit millions of people world-
wide. A better understanding of the mech-
anisms of action of these compounds,
with the ensuing legalization of cannabi-
noids, would be an outstanding scien-
tific breakthrough, leading to a significant
decrease in burden, and improved qual-
ity of life for people with many diseases
and disorders. Conversely, the debate on
the legalization of marijuana for recre-
ational purposes should only take place
after society and the scientific commu-
nity is clearly informed about the potential
complications of the drug or its possible
low-risk profile. In order to do this, how-
ever, it is crucial to separate the wheat from
the chaff, beans from feijoada or—in this
case—cannabinoids from marijuana.
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